Macarulla, T
Cervantes, A
Tabernero, J
Roselló, S
Van Cutsem, E
Tejpar, S
Prenen, H
Martinelli, E
Troiani, T
Laffranchi, B
Jego, V
von Richter, O
Ciardiello, F
Article History
Received: 30 June 2014
Revised: 25 February 2015
Accepted: 25 March 2015
First Online: 19 May 2015
Competing interests
: AC has served as an advisory board member and has received speaker’s fees from Merck Serono. JT has served as a consultant and advisory board member for Amgen, Imclone, Lilly, Merck KGaA, Millenium, Novartis, Roche, Sanofi, Celgene, Chugai and Taiho. EVC has received research funding from Merck KGaA paid to institution. ST has received speaker’s fees from Merck Serono. OvR is an employee of Merck Serono. BL was an employee of Merck Serono and is currently a non-exclusive consultant for Merck KGaA. VJ is an employee of Cytel Inc, a CRO contracted by Merck KGaA. FC has served as an advisory board member for Merck Serono, Bayer, Astellas and Roche and has received research funding from Merck Serono, Bayer and AstraZeneca. TM, SR, HP, EM and TT declare no conflict of interest.